Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37265409.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1043 and PMC identifier 10524714.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival. See related article by Tolmeijer et al., p. 2835.
Medical subject headings
- Circulating Tumor DNA
- Prostatic Neoplasms, Castration-Resistant